In a patient taking lamotrigine, brexpiprazole (Rexulti), buspirone, and methylphenidate (Ritalin) with serum creatinine 1.30 mg/dL, eGFR 73 mL/min/1.73 m², and low BUN‑creatinine ratio, should any medication doses be adjusted or renal function monitored?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Medication Management in Stage 3a CKD

Based on your patient's eGFR of 73 mL/min/1.73 m² (Stage 3a CKD), brexpiprazole (Rexulti) requires dose reduction to a maximum of 2 mg daily for MDD or 3 mg daily for schizophrenia, while lamotrigine, buspirone, and methylphenidate can continue at current doses with enhanced monitoring.

Renal Function Assessment

Your patient has Stage 3a chronic kidney disease with:

  • Creatinine: 1.30 mg/dL (mildly elevated)
  • eGFR: 73 mL/min/1.73 m² (mildly to moderately decreased)
  • Low BUN/creatinine ratio (7): suggests adequate hydration or possible muscle wasting

The KDIGO guidelines classify eGFR 60-89 mL/min/1.73 m² as Stage 2 (mildly decreased), but your patient's creatinine elevation places them in Stage 3a territory, warranting medication review 1, 2, 1.

Medication-Specific Recommendations

Brexpiprazole (Rexulti) - REQUIRES DOSE ADJUSTMENT

The FDA label explicitly states that maximum dosage must be reduced when creatinine clearance <60 mL/minute 3. While your patient's eGFR is 73 mL/min/1.73 m², the elevated creatinine (1.30 mg/dL) indicates reduced renal function requiring caution:

  • For MDD adjunctive treatment: Maximum 2 mg daily (vs. 3 mg in normal renal function)
  • For schizophrenia: Maximum 3 mg daily (vs. 4 mg in normal renal function)
  • Rationale: Patients with renal impairment have higher brexpiprazole exposure, increasing risk of adverse reactions 3

Lamotrigine - NO DOSE ADJUSTMENT NEEDED

Lamotrigine is primarily hepatically metabolized with minimal renal excretion. No dose adjustment is required for eGFR >30 mL/min/1.73 m². Continue current dosing but monitor for signs of accumulation if renal function declines further.

Buspirone - CAUTION, NO FORMAL ADJUSTMENT

Research shows buspirone pharmacokinetics are altered in renal impairment, with significantly higher Cmax and AUC values in patients with reduced kidney function 4. However:

  • No specific FDA dose adjustment guidelines exist
  • Clinical approach: Use conservative dosing (start low, go slow if increasing)
  • Monitor closely for increased sedation, dizziness, or other adverse effects
  • Consider reducing dose by 25-50% if side effects emerge

Methylphenidate (Ritalin) - NO ADJUSTMENT, BUT MONITOR

The FDA label for methylphenidate does not specify renal dose adjustments 5. However, research suggests potential nephrotoxic effects including reduced glomerular filtration and altered sodium transport 6.

Monitoring strategy:

  • Check renal function every 3-6 months
  • Watch for worsening creatinine or eGFR decline
  • Consider alternative ADHD treatments if renal function deteriorates

Monitoring Protocol

KDIGO guidelines recommend prescribers take GFR into account when drug dosing and monitor patients taking potentially nephrotoxic agents regularly 1, 2, 1:

  1. Renal function monitoring: Every 3-6 months

    • Serum creatinine
    • eGFR calculation
    • Electrolytes (especially potassium given psychiatric medications)

  2. Clinical monitoring:

    • Blood pressure (psychiatric medications can affect BP)
    • Signs of drug accumulation (increased sedation, confusion, extrapyramidal symptoms)
    • Hydration status

  3. Drug level monitoring (if available):

    • Consider therapeutic drug monitoring for lamotrigine if clinical response changes

Critical Caveats

The low BUN/creatinine ratio (7) deserves attention: This may indicate:

  • Adequate hydration (reassuring)
  • Low protein intake
  • Reduced muscle mass (which could mean creatinine overestimates true GFR)

If muscle mass is significantly reduced, the actual GFR may be lower than 73 mL/min/1.73 m², making the brexpiprazole dose reduction even more important 1.

Avoid during acute illness: KDIGO recommends temporary discontinuation of renally excreted drugs during serious intercurrent illness that increases AKI risk 1, 2, 1. While these psychiatric medications are not primarily renally excreted, dehydration or acute illness could precipitate further renal decline.

Immediate Action Steps

  1. Reduce brexpiprazole to maximum 2 mg daily (if used for MDD) or 3 mg daily (if used for schizophrenia)
  2. Continue lamotrigine and methylphenidate at current doses
  3. Review buspirone dosing - consider empiric 25% reduction if patient experiences increased side effects
  4. Schedule renal function recheck in 3 months
  5. Ensure adequate hydration to optimize renal perfusion
  6. Avoid nephrotoxic agents: NSAIDs, contrast dye without prophylaxis 1, 2

References

Related Questions

What are the appropriate dosing adjustments for buspirone (Buspar) in patients with renal impairment, including mild to moderate (eGFR 30‑60 mL/min), severe (eGFR <30 mL/min) and those on dialysis?
In a patient with an eGFR of 42 mL/min/1.73 m², which of the following medications require dose adjustments: famotidine 20 mg, adalimumab 30 mg, calcitriol 0.5 µg, atorvastatin 10 mg, venlafaxine 37.5 mg, vitamin D3 2400 IU, and calcium carbonate 18 mg?
Is aripiprazole (Abilify) 2 mg once daily safe for a patient with an estimated glomerular filtration rate of 12 mL/min?
What antipsychotic medication, dose, and dosing frequency should be used for an adult with end‑stage renal disease on dialysis who has persistent visual hallucinations?
In a 41‑year‑old patient with an unspecified mood disorder taking Auvelity (dextromethorphan‑bupropion) 45‑105 mg daily and Caplyta (lumateperone) 10.5 mg daily, who has anemia (low RBC, low hemoglobin, low hematocrit), elevated fasting glucose, high blood urea nitrogen with mildly elevated creatinine, normal liver enzymes, and normal thyroid‑stimulating hormone, what is the appropriate work‑up and management?
How should a 3-week postpartum woman with headache and mild hypertension (blood pressure 140 mmHg) be treated?
What does a paced rhythm on an electrocardiogram indicate?
What treatment plan should be used for a 67-year-old woman with bipolar disorder, anxiety, dementia, and insomnia who has failed trials of multiple antidepressants and is currently on aripiprazole (Abilify) 10 mg without improvement in depression?
In a 6'5", 318‑lb Black male with mixed connective tissue disease, G6PD deficiency, modestly elevated creatine kinase, positive speckled ANA with elevated anti‑U1 RNP, negative anti‑Jo‑1, normal electromyography, and proximal muscle weakness (tight back, shoulder‑blade discomfort, arm and leg weakness), what specific type of myositis is most likely (necrotizing, dermatomyositis, polymyositis, or inflammatory myopathy) and what is the expected prognosis?
What is the appropriate evaluation and management for a patient presenting with dark stool (possible melena) and a positive fecal occult blood test?
How should I evaluate and manage bloating in an adult without red‑flag symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.